Possible adverse effects include discomfort of the liner of the heart, fluid in the lung area or around the heart, bleeding, stroke and clots. In the study, 106 patients with frequent episodes of atrial fibrillation had been randomly assigned to undergo ablation and 61 equivalent sufferers were randomly designated to get drug therapy. All patients had skilled at least three episodes of atrial fibrillation through the previous half a year and got failed at least one try to control the rhythm with drugs. The study was funded by Biosense Webster, making the ThermoCool catheter used in the trial. Wilber is a consultant to the ongoing company. The study was the largest to time to compare ablation to drug therapy for atrial fibrillation. Earlier studies involved solitary centers and smaller sample sizes, Wilber stated.The researchers say the technology could possibly be used for aesthetic anti-ageing treatments also, and to treat conditions such as acne.. Amgen reports that Phase 3 DESCARTES research for raised chlesterol meets primary endpoint Amgen today announced that the Stage 3 DESCARTES research evaluating the long-term 52-week protection and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of % reduction from baseline in low-density lipoprotein cholesterol at week 52. The mean % decrease in LDL-C, or poor cholesterol, was consistent with the results seen in the 52-week analysis of the Phase 2 OSLER study.